…
Ayujoy Herbals Ltd., a research and testing organization, provides technical and regulatory consulting for biotechnical products, pharmaceuticals, diagnostics, medical equipment, and devices. The company serves various pharmaceutical companies in India and Southeast Asia to get FDA approval and facilitate exports of pharmaceuticals, and medical products and devices to the United States. Its services include analytical QC, QA functions, readiness for inspections, compliance, validation, clinical trial management, regulatory/legal, preparation of regulatory filings, compliance assessments, risk assessments, mock FDA audits, medical device support, CMC support, GMP training, facility layout consulting, and training, as well as utilities, process, IT, computer, and cleaning validation services. The company was incorporated in 2008 and is based in Mumbai, India.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Public disclosures for Ayujoy Herbals Ltd (AJOY.US) are limited and filings do not provide a clear, independently verifiable description of its operations; the company is listed on the OTC Pink market, which typically hosts small issuers with low reporting requirements. Because material long-term growth drivers are not publicly documented, investors should monitor filings closely and may consider the security only if they are comfortable with speculative, low-disclosure small-cap equities.
The most important investment risks are limited and inconsistent public disclosure, very low trading liquidity, potential financial and governance opacity, and heightened regulatory or capitalization uncertainty.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2017-12-31 | 2016-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2017-12-31 | 2016-12-31 |
| Income before tax | -0.14M | -0.67M | -0.43M | 7.66M | 4.44M |
| Net income | -0.14M | -0.67M | -0.43M | 6.39M | 3.27M |
| Gross profit | - | 0.16M | - | 18.99M | 18.26M |
| Ebit | -0.30M | -0.67M | -0.66M | 7.66M | 4.44M |
| Ebitda | -0.14M | -0.67M | -0.43M | 8.07M | 5.02M |
| Depreciation and amortization | 0.17M | 0.00M | 0.24M | 0.41M | 0.58M |
| Operating income | -0.07M | -0.67M | -0.43M | 7.66M | 7.22M |
| Other operating expenses | 0.07M | 0.86M | 0.43M | 48.31M | 48.64M |
| Income tax expense | -0.17M | 0.00M | -0.24M | 1.27M | 1.17M |
| Total revenue | - | 0.19M | - | 55.97M | 55.87M |
| Total operating expenses | 0.07M | 0.83M | 0.43M | 11.33M | 11.04M |
| Cost of revenue | - | 0.02M | - | 36.98M | 37.60M |
| Total other income expense net | -0.07M | -0.00M | 0.00M | 0.00M | -2.78M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2017-12-31 | 2016-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2017-12-31 | 2016-12-31 |
| Total assets | 0.00M | - | 1.60M | 42.98M | 36.59M |
| Intangible assets | - | - | 1.50M | - | - |
| Other current assets | - | - | - | 13.87M | 11.74M |
| Total liab | 0.06M | - | 0.93M | 0.06M | 0.06M |
| Total stockholder equity | -0.06M | - | 0.67M | 42.93M | 36.53M |
| Other current liab | 0.06M | - | - | 0.00M | 0.00M |
| Common stock | 0.62M | - | 0.60M | 0.47M | 0.47M |
| Retained earnings | -1.40M | - | -0.59M | 40.57M | 34.18M |
| Cash | 0.00M | - | 0.08M | 0.41M | 0.40M |
| Total current liabilities | 0.06M | - | 0.00M | 0.06M | 0.06M |
| Current deferred revenue | - | - | - | 0.05M | 0.05M |
| Net debt | -0.00M | - | 0.85M | -0.41M | -0.40M |
| Short term debt | - | - | - | - | 0.00M |
| Short long term debt total | - | - | 0.93M | - | - |
| Other stockholder equity | 0.71M | - | 0.66M | 1.89M | 1.89M |
| Total current assets | 0.00M | - | 0.10M | 32.44M | 26.19M |
| Short term investments | - | - | - | 17.04M | 13.02M |
| Net receivables | - | - | - | 1.08M | 1.01M |
| Inventory | - | - | 0.02M | 0.03M | 0.03M |
| Accounts payable | 0.00M | - | 0.00M | 0.00M | 0.00M |
| Non currrent assets other | - | - | - | 9.90M | 9.66M |
| Non current assets total | - | - | 1.50M | 10.54M | 10.40M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2017-12-31 | 2016-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2017-12-31 | 2016-12-31 |
| Total cashflows from investing activities | - | - | - | - | -1.53M |
| Total cash from financing activities | 0.00M | -0.93M | 0.72M | - | - |
| Net income | -0.14M | -0.67M | -0.43M | 6.39M | 3.27M |
| Change in cash | 0.00M | -0.08M | -0.34M | 0.01M | 0.02M |
| Begin period cash flow | 0.00M | 0.08M | 0.41M | 0.40M | 0.38M |
| End period cash flow | 0.00M | 0.00M | 0.08M | 0.41M | 0.40M |
| Total cash from operating activities | -0.00M | -0.64M | -0.45M | 6.72M | 1.54M |
| Depreciation | - | 0.00M | - | 0.41M | 0.58M |
| Other cashflows from investing activities | - | - | - | - | -0.25M |
| Change to inventory | 0.00M | 0.02M | -0.02M | -0.00M | 0.00M |
| Change to account receivables | - | - | - | -0.07M | -0.02M |
| Other cashflows from financing activities | 0.00M | -0.93M | 0.72M | -6.71M | - |
| Capital expenditures | 0.00M | 0.00M | 0.28M | 0.55M | 0.14M |
| Change in working capital | 0.06M | 0.02M | -0.02M | -0.08M | -0.02M |
| Other non cash items | 0.07M | -0.02M | 0.02M | 0.89M | -1.12M |
| Free cash flow | -0.00M | -0.64M | -0.73M | 6.18M | 1.40M |
Sector: Consumer Defensive Industry: Packaged Foods
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
|---|---|---|---|---|---|---|
| AJOY Ayujoy Herbals Ltd |
- -% |
0.00 | 0.02 | - | 0.00 | - |
| NSRGF Nestle SA |
- -% |
99.03 | 26.86 | 18.76 | 3.13 | 7.10 |
| NSRGY Nestle SA ADR |
0.85 0.85% |
101.06 | 26.82 | 18.66 | 3.18 | 7.07 |
| DANOY Danone PK |
-0.03 0.20% |
14.93 | 24.23 | 17.64 | 1.88 | 2.57 |
| GPDNF Danone S.A |
- -% |
74.00 | 20.30 | 14.75 | 1.65 | 2.24 |
Ayujoy Herbals Ltd., a research and testing organization, provides technical and regulatory consulting for biotechnical products, pharmaceuticals, diagnostics, medical equipment, and devices. The company serves various pharmaceutical companies in India and Southeast Asia to get FDA approval and facilitate exports of pharmaceuticals, and medical products and devices to the United States. Its services include analytical QC, QA functions, readiness for inspections, compliance, validation, clinical trial management, regulatory/legal, preparation of regulatory filings, compliance assessments, risk assessments, mock FDA audits, medical device support, CMC support, GMP training, facility layout consulting, and training, as well as utilities, process, IT, computer, and cleaning validation services. The company was incorporated in 2008 and is based in Mumbai, India.
| Name | Title | Year Born |
|---|---|---|
| Ms. Dipika Purohit | Chairman, Chief Exec. Officer and Pres | NA |
| Ms. Dipika Purohit | Chairman, Chief Executive Officer and President | NA |
| Mr. William Murray | Senior Vice President of International Sales & Marketing | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.